Surface Ophthalmics is dedicated to advancing the treatment of dry eye syndrome (DES) through a diverse pipeline of innovative and patented therapies. Their approach encompasses both prescription (Rx) and over-the-counter (OTC) eye drops, targeting the multifactorial nature of DES, which includes tear film instability, ocular surface inflammation, and neurosensory abnormalities. The company aims to address the full spectrum of dry eye conditions, from episodic discomfort to chronic symptoms, thereby providing eye care professionals (ECPs) with tailored solutions that meet the unique needs of each patient. This comprehensive strategy is designed to empower ECPs to effectively manage the signs and symptoms of dry eye, as well as the underlying causes associated with both natural occurrences and post-surgical cases.

Among the key products in development are Kera Sol Tears, an OTC artificial tear solution for temporary relief of dryness, and Mycosol (Surf-101), a first-in-class prescription eye drop that utilizes mycophenolate to provide sustained immunosuppressive effects at the ocular surface. Mycosol is designed to address inflammation by targeting T-lymphocytes and B-lymphocytes, while also promoting mucin production to enhance tear film stability. Additionally, Betasol (Surf-201) combines betamethasone with a proprietary vehicle to alleviate postoperative inflammation and pain. Through these advanced therapies, Surface Ophthalmics aims to fill critical gaps in current dry eye management, offering ECPs effective options for both short-term and chronic treatment scenarios.

United States

Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases. We are striving to solve key patient needs in eye care through leveraging deep expertise, a bold approach, an eye toward efficiency, and a clear, differentiated clinical advantages. Our current drug pipeline consists of three proprietary drug candidates, all utilizing Klarity®, a patented delivery vehicle. We are led by an experienced and proven management team and board of directors with over 80 years of ophthalmology related professional experience.

Surface Ophthalmics

Company Details